

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>Sanderling Venture Partners VI LP</u> (Last) (First) (Middle) 1300 S. EL CAMINO REAL SUITE 203 (Street) SAN MATEO CA 94402 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>CalciMedica, Inc. [CALC]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 01/23/2024	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person
	Rule 10b5-1(c) Transaction Indication <input type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	01/23/2024		p ⁽¹⁾		243,356	A	\$3.702	946,744	D	
Common Stock	01/23/2024		p ⁽¹⁾		144,676	A	\$3.702	727,433	I	By Sanderling Venture Partners VI Co-Investment Fund, L.P.
Common Stock	01/23/2024		p ⁽¹⁾		194,472	A	\$3.702	435,148	I	By Sanderling Ventures VII, L.P.
Common Stock	01/23/2024		p ⁽¹⁾		51,032	A	\$3.702	114,260	I	By Sanderling Ventures VII (Canada), L.P.
Common Stock	01/23/2024		p ⁽¹⁾		13,184	A	\$3.702	27,609	I	By Sanderling Ventures VII Annex Fund, L.P.
Common Stock	01/23/2024		p ⁽¹⁾		3,920	A	\$3.702	21,602	I	By Sanderling Ventures Management VI
Common Stock	01/23/2024		p ⁽¹⁾		28,744	A	\$3.702	30,292	I	By Sanderling Ventures Management VII

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Warrant	\$5.36	01/23/2024		p ⁽¹⁾		121,678		01/23/2024 ⁽²⁾	12/31/2024 ⁽²⁾	Common Stock	121,678	\$0.125	121,678	D	
Warrant	\$7.15	01/23/2024		p ⁽¹⁾		121,678		01/23/2024 ⁽³⁾	12/31/2026 ⁽³⁾	Common Stock	121,678	\$0.125	121,678	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Warrant	\$5.36	01/23/2024		P ⁽¹⁾		72,338		01/23/2024 ⁽²⁾	12/31/2024 ⁽²⁾	Common Stock	72,338	\$0.125	72,338	I	By Sanderling Venture Partners VI Co-Investment Fund, L.P.
Warrant	\$7.15	01/23/2024		P ⁽¹⁾		72,338		01/23/2024 ⁽³⁾	12/31/2026 ⁽³⁾	Common Stock	72,338	\$0.125	72,338	I	By Sanderling Venture Partners VI Co-Investment Fund, L.P.
Warrant	\$5.36	01/23/2024		P ⁽¹⁾		97,236		01/23/2024 ⁽²⁾	12/31/2024 ⁽²⁾	Common Stock	97,236	\$0.125	97,236	I	By Sanderling Ventures VII, L.P.
Warrant	\$7.15	01/23/2024		P ⁽¹⁾		97,236		01/23/2024 ⁽³⁾	12/31/2026 ⁽³⁾	Common Stock	97,236	\$0.125	97,236	I	By Sanderling Ventures VII, L.P.
Warrant	\$5.36	01/23/2024		P ⁽¹⁾		25,516		01/23/2024 ⁽²⁾	12/31/2024 ⁽²⁾	Common Stock	25,516	\$0.125	25,516	I	By Sanderling Ventures VII (Canada), L.P.
Warrant	\$7.15	01/23/2024		P ⁽¹⁾		25,516		01/23/2024 ⁽³⁾	12/31/2026 ⁽³⁾	Common Stock	25,516	\$0.125	25,516	I	By Sanderling Ventures VII (Canada), L.P.
Warrant	\$5.36	01/23/2024		P ⁽¹⁾		6,592		01/23/2024 ⁽²⁾	12/31/2024 ⁽²⁾	Common Stock	6,592	\$0.125	6,592	I	By Sanderling Ventures VII Annex Fund, L.P.
Warrant	\$7.15	01/23/2024		P ⁽¹⁾		6,592		01/23/2024 ⁽³⁾	12/31/2026 ⁽³⁾	Common Stock	6,592	\$0.125	6,592	I	By Sanderling Ventures VII Annex Fund, L.P.
Warrant	\$5.36	01/23/2024		P ⁽¹⁾		1,960		01/23/2024 ⁽²⁾	12/31/2024 ⁽²⁾	Common Stock	1,960	\$0.125	1,960	I	By Sanderling Ventures Management VI
Warrant	\$7.15	01/23/2024		P ⁽¹⁾		1,960		01/23/2024 ⁽³⁾	12/31/2026 ⁽³⁾	Common Stock	1,960	\$0.125	1,960	I	By Sanderling Ventures Management VI
Warrant	\$5.36	01/23/2024		P ⁽¹⁾		14,372		01/23/2024 ⁽²⁾	12/31/2024 ⁽²⁾	Common Stock	14,372	\$0.125	14,372	I	By Sanderling Ventures Management VII
Warrant	\$7.15	01/23/2024		P ⁽¹⁾		14,372		01/23/2024 ⁽³⁾	12/31/2026 ⁽³⁾	Common Stock	14,372	\$0.125	14,372	I	By Sanderling Ventures Management VII

1. Name and Address of Reporting Person*
[Sanderling Venture Partners VI LP](#)

 (Last) (First) (Middle)
 1300 S. EL CAMINO REAL SUITE 203

 (Street)
 SAN MATEO CA 94402

 (City) (State) (Zip)

1. Name and Address of Reporting Person*
[Sanderling Venture Partners VI Co Investment Fund LP](#)

 (Last) (First) (Middle)
 1300 S EL CAMINO REAL
 SUITE 203

(Street)	SAN MATEO	CA	94402
(City)	(State)	(Zip)	
1. Name and Address of Reporting Person*			
Sanderling Ventures Management VI			
(Last)	(First)	(Middle)	
1300 S EL CAMINO REAL SUITE 203			
(Street)	SAN MATEO	CA	94402
(City)	(State)	(Zip)	
1. Name and Address of Reporting Person*			
Sanderling Ventures VII, L.P.			
(Last)	(First)	(Middle)	
1300 S. EL CAMINO REAL SUITE 203			
(Street)	SAN MATEO	CA	94402
(City)	(State)	(Zip)	
1. Name and Address of Reporting Person*			
Sanderling Ventures VII Annex Fund, L.P.			
(Last)	(First)	(Middle)	
1300 S EL CAMINO REAL SUITE 203			
(Street)	SAN MATEO	CA	94402
(City)	(State)	(Zip)	
1. Name and Address of Reporting Person*			
Sanderling Ventures VII (Canada), L.P.			
(Last)	(First)	(Middle)	
1300 S. EL CAMINO REAL SUITE 203			
(Street)	SAN MATEO	CA	94402
(City)	(State)	(Zip)	
1. Name and Address of Reporting Person*			
Sanderling Ventures Management VII			
(Last)	(First)	(Middle)	
1300 S. EL CAMINO REAL SUITE 203			
(Street)	SAN MATEO	CA	94402
(City)	(State)	(Zip)	

Explanation of Responses:

1. The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.
2. The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.
3. The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.

[/s/ Sanderling Venture Partners VI, L.P., By: /s/ Timothy C. Mills, Managing Director of Middleton, McNeil & Mills Associates VI, L.P., its General Partner](#) 01/25/2024

[/s/ Sanderling Venture Partners VI Co-Investment Fund, L.P.](#) 01/25/2024

By: /s/ Timothy C. Mills,
Managing Director of
Middleton, McNeil & Mills
Associates VI, LLC, its General
Partner

/s/ Sanderling Ventures VII
(Canada), L.P., By: /s/ D.
Michael Dixon, President of
Sanderling Ventures VII 01/25/2024
(Canada) GP Inc., General
Partner of Sanderling Ventures
VII (Canada) G.P., L.P., its
General Partner

/s/ Sanderling Ventures VII, L.P.
, By: /s/ Timothy C. Mills,
Managing Director of M4 01/25/2024
Partners VII, LLC, its General
Partner

/s/ Sanderling Ventures VII
Annex Fund, L.P., By: /s/
Timothy C. Mills, Managing 01/25/2024
Director of M4 Partners VII
Annex, LLC, its General Partner

/s/ Sanderling Ventures
Management VII, By: /s/ 01/25/2024
Timothy C. Mills, Owner

/s/ Sanderling Ventures
Management VI, By: /s/ 01/25/2024
Timothy C. Mills, Owner

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.